{"result": "(\"entity\"<|>INTRALIPID<|>ORGANIZATION<|>Intralipid is a lipid emulsion used in pediatric parenteral nutrition, containing 100% soybean oil.)\n##\n(\"entity\"<|>CLINOLEIC<|>ORGANIZATION<|>Clinoleic is a lipid emulsion used in pediatric parenteral nutrition, containing 20% soybean oil and 80% olive oil.)\n##\n(\"entity\"<|>LIPOFUNDINA<|>ORGANIZATION<|>Lipofundina is a lipid emulsion used in pediatric parenteral nutrition, containing 50% medium-chain triglycerides.)\n##\n(\"entity\"<|>LIPOPLUS<|>ORGANIZATION<|>Lipoplus is a lipid emulsion used in pediatric parenteral nutrition, containing a mix of oils including 10% fish oil.)\n##\n(\"entity\"<|>SMOFLIPID<|>ORGANIZATION<|>SMOFlipid is a lipid emulsion used in pediatric parenteral nutrition, containing a mix of soybean, olive, and fish oils.)\n##\n(\"entity\"<|>OMEGAVEN<|>ORGANIZATION<|>Omegaven is a lipid emulsion used in pediatric parenteral nutrition, consisting solely of fish oil and used for patients with liver disease.)\n##\n(\"entity\"<|>DHA<|>EVENT<|>DHA (docosahexaenoic acid) is an omega-3 fatty acid important for pediatric nutrition.)\n##\n(\"entity\"<|>EPA<|>EVENT<|>EPA (eicosapentaenoic acid) is an omega-3 fatty acid important for pediatric nutrition.)\n##\n(\"entity\"<|>CARNITINE<|>EVENT<|>Carnitine is a nutrient that transports fatty acids into the mitochondria for energy production, essential in pediatric nutrition.)\n##\n(\"relationship\"<|>INTRALIPID<|>CLINOLEIC<|>Both Intralipid and Clinoleic are lipid emulsions used in pediatric parenteral nutrition, differing in their oil composition.<|>5)\n##\n(\"relationship\"<|>INTRALIPID<|>LIPOFUNDINA<|>Both Intralipid and Lipofundina are lipid emulsions used in pediatric parenteral nutrition, with Intralipid containing only soybean oil and Lipofundina containing medium-chain triglycerides.<|>5)\n##\n(\"relationship\"<|>INTRALIPID<|>LIPOPLUS<|>Both Intralipid and Lipoplus are lipid emulsions used in pediatric parenteral nutrition, with different oil compositions.<|>5)\n##\n(\"relationship\"<|>INTRALIPID<|>SMOFLIPID<|>Both Intralipid and SMOFlipid are lipid emulsions used in pediatric parenteral nutrition, with SMOFlipid containing a mix of oils including fish oil.<|>5)\n##\n(\"relationship\"<|>INTRALIPID<|>OMEGAVEN<|>Both Intralipid and Omegaven are lipid emulsions used in pediatric parenteral nutrition, but Omegaven is specifically for patients with liver disease.<|>5)\n##\n(\"relationship\"<|>CLINOLEIC<|>LIPOFUNDINA<|>Both Clinoleic and Lipofundina are lipid emulsions used in pediatric parenteral nutrition, differing in their oil compositions.<|>5)\n##\n(\"relationship\"<|>CLINOLEIC<|>LIPOPLUS<|>Both Clinoleic and Lipoplus are lipid emulsions used in pediatric parenteral nutrition, with different oil compositions.<|>5)\n##\n(\"relationship\"<|>CLINOLEIC<|>SMOFLIPID<|>Both Clinoleic and SMOFlipid are lipid emulsions used in pediatric parenteral nutrition, differing in their oil compositions.<|>5)\n##\n(\"relationship\"<|>CLINOLEIC<|>OMEGAVEN<|>Both Clinoleic and Omegaven are lipid emulsions used in pediatric parenteral nutrition, but Omegaven is specifically for patients with liver disease.<|>5)\n##\n(\"relationship\"<|>LIPOFUNDINA<|>LIPOPLUS<|>Both Lipofundina and Lipoplus are lipid emulsions used in pediatric parenteral nutrition, differing in their oil compositions.<|>5)\n##\n(\"relationship\"<|>LIPOFUNDINA<|>SMOFLIPID<|>Both Lipofundina and SMOFlipid are lipid emulsions used in pediatric parenteral nutrition, differing in their oil compositions.<|>5)\n##\n(\"relationship\"<|>LIPOFUNDINA<|>OMEGAVEN<|>Both Lipofundina and Omegaven are lipid emulsions used in pediatric parenteral nutrition, but Omegaven is specifically for patients with liver disease.<|>5)\n##\n(\"relationship\"<|>LIPOPLUS<|>SMOFLIPID<|>Both Lipoplus and SMOFlipid are lipid emulsions used in pediatric parenteral nutrition, differing in their oil compositions.<|>5)\n##\n(\"relationship\"<|>LIPOPLUS<|>OMEGAVEN<|>Both Lipoplus and Omegaven are lipid emulsions used in pediatric parenteral nutrition, but Omegaven is specifically for patients with liver disease.<|>5)\n##\n(\"relationship\"<|>SMOFLIPID<|>OMEGAVEN<|>Both SMOFlipid and Omegaven are lipid emulsions used in pediatric parenteral nutrition, but Omegaven is specifically for patients with liver disease.<|>5)\n##\n(\"relationship\"<|>DHA<|>EPA<|>DHA and EPA are both omega-3 fatty acids important for pediatric nutrition and are often included in lipid emulsions.<|>7)\n##\n(\"relationship\"<|>CARNITINE<|>DHA<|>Carnitine is essential for the metabolism of fatty acids, including DHA, which is important in pediatric nutrition.<|>6)\n##\n(\"relationship\"<|>CARNITINE<|>EPA<|>Carnitine is essential for the metabolism of fatty acids, including EPA, which is important in pediatric nutrition.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 3-4 g/kg/día (0,13-0,17                cias significativas con respecto a los parámetros de co-\ng/kg/h) en lactantes y de 2-3 g/kg/día (0,08-0,13 g/            lestasis entre el uso de fórmulas a base de aceite de\nkg/h) en niños mayores de 2 años12 . Se recomienda              soja (Intralipid®) y las soluciones mixtas con aceite\nincluirlos en la bolsa con el resto de los nutrientes           de pescado (SMOFlipid®; Lipoplus®) cuando se utilizan\n(mezclas ternarias)25 e infundirlos a lo largo de 24 ho-        a corto plazo en neonatos o niños de mayor edad26. Se\nras. En caso de ciclado de la parenteral, se infundirán         ha visto que en niños con nutrición parenteral prolon-\ndurante el mismo tiempo que el resto de componen-               gada, el uso de soluciones mixtas con aceite de pesca-\ntes de la NP. No existe evidencia de que aumentos pro-          do puede contribuir a proteger frente al desarrollo de\ngresivos en la cantidad de lípidos mejore su tolerancia,        colestasis26. Por último, la solución Omegaven®, a base\naunque aumentos de 0,5-1 g/kg/día, especialmente                únicamente de aceite de pescado, ha mostrado su efi-\nen RNPT, pueden ayudar a controlar la hipertrigliceri-          cacia en el tratamiento de rescate de pacientes con\ndemia. Los niveles de triglicéridos en sangre se deben          enfermedad hepática relacionada con la NP, especial-\nmonitorizar siempre en pacientes que estén recibien-            mente en los afectos de síndrome de intestino cor-\ndo lípidos por vía intravenosa, especialmente en aque-          to27, 28 , aunque la mejoría en la colestasis no siempre se\n\nllos casos de mayor riesgo de hiperlipidemia (RN de             asocia a menor progresión de la fibrosis29, 30. Hay que\n---\n                                                 Tema 55.      Nutrición parenteral en el paciente pediátrico: vías y fórmulas                 867\n\n\n\nTabla 5.    Emulsiones lipídicas disponibles en pediatría.\n\n\n\n          Componentes                   Intralipid®      Clinoleic®        Lipofundina®          Lipoplus®        SMOFlipid®        Omegaven®\n                                          (20%)             (20%)              (20%)               (20%)             (20%)             (10%)\n  Aceite de soja (%)                        100               20                  50                  40                30                 0\n  TCM (%)                                     0                0                  50                  50                30                 0\n  Aceite de oliva (%)                         0               80                   0                  0                 25                 0\n  Aceite de pescado (%)                       0                0                   0                  10                15               100\n  Vitamina E (mg/l)                          38               32              85+/–20            190+/–30              200            150-296\n  Ácido linoleico (%)                        53              18,7                29,1               25,7              37,2               4,4\n  Ácido alfa-linolénico (%)                   8               2,3                4,5                 3,4               4,7               1,8\n  EPA (%)                                     0                0                   0                 3,7               4,7               19,2\n  DHA (%)                                     0                0                   0                 2,5               4,4               12,1\n  Ratio n-6:n-3                              7:1              9:1                7:1                2,7:1             2,5:1              1:8\n\n\n\nDHA: ácido docohexaenoico; EPA: ácido eicosapentaenoico; TCM: triglicéridos de cadena media.\n\n\n\ntener en cuenta que este tipo de solución no se puede                         5.3.   Aminoácidos (AA)\nutilizar de forma exclusiva en pacientes pediátricos du-                         Las proteínas se suministran en forma de soluciones\nrante un tiempo prolongado, por el riesgo asociado a                          de aminoácidos (AA) y son esenciales para mantener la\ndesarrollar un déficit de ácidos grasos esenciales. Este                      masa corporal magra. Su aporte debe minimizar el ca-\nriesgo podría no existir en caso de que el paciente reci-                     tabolismo proteico inducido por el estrés y el ayuno, y\nba también alimentación por vía oral o enteral, pero                          favorecer la síntesis proteica sin producir complicacio-\neso aún está por determinar.                                                  nes hepáticas y/o renales. Los requerimientos proteicos\n   La carnitina es el transportador de los ácidos grasos                      se han establecido sobre las bases\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}